| March 12, 2021 |
CASI Pharmaceuticals To Host Business Update Call
Date/Time: Thursday, March 12, 2021 8:00 AM (ET)
On the call, CASI’s Chairman & CEO will provide an update on recent business developments and review upcoming milestones. The conference call can be accessed by dialing (877) 405-1224 (U.S.), (86) 400-120-2840 (China), (800) 965-561 (Hong Kong) to listen to the live presentation. The live webcast can be accessed at the following link: https://78449.themediaframe.com/dataconf/productusers/casi/mediaframe/44098/indexl.html
|
| January 28, 2021 | BioInvent KOL Call: BI-1206 for Relapsed or Refractory Non-Hodgkin’s Lymphoma
Date/Time: Thursday, Jan 28, 2021 11:30 AM (ET)
Biovent will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin’s Lymphoma.
Click here for the press release.
Click here for presentation.
|
| January 11, 2021 | H.C.Wainwright Bioconnect Conference
Date/Time: Monday, January 11th at 6:00 AM (ET)
Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the H.C.Wainwright Bioconnect Conference.
Webcast recording
|
| November 9, 2020 | Third Quarter Highlights
Date/Time: Monday, November 9 from 4:30pm ET
CASI’s Chairman & CEO will provide an update on recent business developments and review upcoming milestones. The conference call can be accessed by dialing (833) 647-4459 (U.S.), (800) 870-0181 (China), (400) 682-8629 (China, domestic), (580) 86567 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 8835514.
|
| October 4, 2020 | American Association of Blood Banks (AABB) Virtual Annual Meeting
Session: Plenary Oral Abstract Session
Title: CID-103, an Anti-CD38 Monoclonal Antibody Demonstrates Decreased RBC Binding and Decreased Interference with Pretransfusion Test Methods
Poster Number: P-IG-9
Date/Time: Sunday, Oct. 4 from 1:15-2:15pm ET
|
| September 23, 2020 | Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 23rd
Time: 1:40 PM (EDT)
Notice: CASI will no longer be presenting at this event
|
| September 14, 2020 | H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14th
Time: 12:30 PM (EDT)
https://wsw.com/webcast/hcw7/casi/1588480
|
| August 10, 2020 | CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020
The Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.
On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing (833) 647-4459 (U.S.), (800) 870-0181 (China), (400) 682-8629 (China, domestic), 800933597 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 5223239. Participants dialing in via International Toll-Free Service (ITFS) numbers will be required to provide the following passcode to join the conference call: 8336474459, 6025859887.
|
| June 16, 2020 | Annual Meeting
Meeting materials and proxy statement available at
Annual Meeting Download
https://www.casipharmaceuticals.com/investor-relations/annual-stockholders-meeting-notice-and-proxy/
|
| June 4, 2020, 4:00 p.m. ET | Jefferies 2020 Healthcare Conference
Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET. The conference will be held in a virtual meeting format.
Meeting link
|
| May 11, 2020 | Conference Call - First Quarter Highlights
The Company will host a conference call reviewing the first quarter highlights at 4:30 p.m. ET on Monday, May 11, 2020. On the call, CASI’s Chairman & CEO will provide an update on the Company’s business and upcoming milestones. The conference call can be accessed by dialing (833) 647-4459 (U.S.), 8008700181 (China), 58086567 (Hong Kong) to listen to the live conference call. The conference ID number for the live call is 8716619.
|
| Apr 07, 2020 | CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business
update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation,
participants will be able to submit questions electronically with answers provided by the discretion
of the company on an individual basis afterwards. Details are as follows:
Date/Time:
Tuesday, April 7, at 11:00a.m./p.m. EDT
To access the archived presentation, please login at:
Archive
https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html
|
| Mar 16, 2020 | Full Year 2019 Financial Results Conference Call
The Company will host a conference call reviewing the full year 2019 highlights at 4:30 p.m. ET on
Monday, March 16, 2020. On the call, CASI’s Chairman & CEO will provide an update on the
Company’s business and upcoming milestones. The conference call will be conducted in English, and
can be accessed by dialing (833) 647-4459 (U.S.), 8008700181 (China), 58086567 (Hong Kong) to listen
to the live conference call. The conference ID number for the live call is 5894813.
|
| Sep 10, 2019 | Key Opinion Leader (KOL) Symposium
On September 10th in New York City, CASI Pharmaceuticals hosted a key opinion leader (KOL) symposium
addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China
biopharmaceutical market. The meeting featured presentations by Nobel Prize winning immunologist
James P. Allison, Ph.D. and the former head of Chinese National Medical Product Administration
(NMPA), the Chinese FDA, Dr. Ruyi He, M.D. In addition to the presentations there was a panel and
interactive Q&A session moderated by Brad Loncar, a renowned blogger and pundit on the China
pharmaceutical space. Participating in the panel were KOL speakers Dr. James Allison and Dr. Ruyi He
along with CASI CEO Wei-Wu He, Ph.D.; Lynda Chin, M.D. and President and CEO of Apricity Health LLC;
Lulu Lv, M.D., Ph.D. and CEO of Juventas Cell Therapy; and Jinzi Wu, Ph.D. and Chairman and CEO of
Ascletis. Among many subjects addressed on the panel, the group discussed where they saw the biotech
industry going in five years and more specifically, where would China’s biopharma industry be in
five years.
Event Video
|
| Sep 10, 2019 | NASDAQ Bell Ringing
On September 10th, at the NASDAQ MarketSite in Times Square, CASI Pharmaceuticals had the honor of
ringing the closing bell for the NASDAQ exchange. CASI CEO Wei-Wu He did the honors with the rest of
the CASI team in attendance.
|
